Chemopreventive effects of Frondanol A5, a Cucumaria frondosa extract, against rat colon carcinogenesis and inhibition of human colon cancer cell growth

Cancer Prevention Research

Volumn 3, Issue 1, 2010, Pages 82-91

  Janakiram, Naveena B ^a   Mohammed, Altaf ^a   Zhang, Yuting ^a   Choi, Chang In ^a   Woodward, Carl ^b   Collin, Peter ^b   Steele, Vernon E ^c   Rao, Chinthalapally V ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b Coastside Bio Resources ^*  (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZOXYMETHANE; CELL NUCLEUS ANTIGEN; CUCUMARIA FRONDOSA EXTRACT; CYCLIN DEPENDENT KINASE INHIBITOR 1; FRONDANOL A 5; UNCLASSIFIED DRUG; CYCLINE; GLYCOLIPID; H2AFX PROTEIN, HUMAN; HISTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER GROWTH; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HCT116; COLON CANCER; COLON CARCINOGENESIS; CONTROLLED STUDY; CUCUMARIA FRONDOSA; DIET; DOWN REGULATION; DRUG EFFICACY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PHOSPHORYLATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SEA CUCUMBER; UPREGULATION; ANIMAL; CELL SEPARATION; CHEMISTRY; CHEMOPROPHYLAXIS; COLON TUMOR; CUCUMARIA; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CELL SEPARATION; CHEMOPREVENTION; COLONIC NEOPLASMS; CUCUMARIA; FLOW CYTOMETRY; GLYCOLIPIDS; HCT116 CELLS; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS;

EID: 77649198124     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0112     Document Type: Article

References (46)

1. American Cancer Society. Cancer Facts and Figures 2008. Atlanta (GA): 2008.
2. Willett WC. Balancing life-style and genomics research for disease prevention. Science 2002;296:695-8.
3. Newman DJ, Crag GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. Nat Prod 2003;66:1022-37.
4. Nagle DG, Zhou YD, Mora FD, Mohammed KA, Kim YP. Mechanism targeted discovery of antitumor marine natural products. Curr Med Chem 2004;11:1725-56.
5. Balunas MJ, Chai HB, Kinghorn AD. Drug discovery from natural sources. AAPS Journal 2006;8:E239-53.
6. Rajasekaran A, Sivagnanam G, Xavier R. Nutraceuticals as therapeutic agents: a review research. J Pharm Tech 2008;1:328-40.
7. Adrian TE. Novel marine-derived anti-cancer agents. Curr Pharm Des 2007;13:3417-26.
8. Cancer Facts & Figures-2006. American Cancer Society Publication. http://www.cancer.org.
9. Li X-Q, Roginsky A, Ding X-Z, et al. The triterpenoid Frondoside A from the sea cucumber Cucumaria frondosa inhibits proliferation of human pancreatic cancer cells in vivo and in vitro. J Nutr 2004;134:3521S.
10. Collin P, Adrain TE, Roginsky A, et al. Frondanol A5: A novel nutrapreventive and therapeutic agent derived from sea cucumber showing promising anti-proliferative, anti-inflammatory and anti-angiogenic activities. Abstract A80, Chemoprevention-Experimental/Molecular: Biological Agents. 5th AACR international Conference on frontiers in cancer prevention research 2006 Nov 12-15.
11. Kelly MS. Echinoderms: their culture and bioactive compounds. Prog Mol Subcell Biol 2005;39:139-65.
12. Borsig L, Wang L, Cavalcante MCM, et al. Selectin blocking activity of a fucosylated chondroitin sulfate glycosaminoglycan from sea cucumber. Effect on tumor metastasis and neutrophil recruitment. J Biol Chem 2007;282:14984-91.
13. http://www.seacucumber.com
14. Janakiram NB, Steele VE, Rao CV. Estrogen receptor β as a potential target for colon cancer prevention: Chemoprevention of azoxymethane-Induced colon carcinogenesis by raloxifene in F344 rats. Cancer Prev Res 2009;2:52-9.
15. Zhivotovsky B, Orrenius S. Caspase-2 function in response to DNA damage. Biochem Biophys Res Commun 2005;331:859-67.
16. Chen CL, Lin CF, Chiang CW, Jan MS, Lin YS. Lithium inhibits ceramide - and etoposide-induced protein phosphatase 2A methylation, Bcl-2 dephosphorylation, caspase-2 activation, and apoptosis. Mol Pharmacol 2006;70:510-7.
17. Gao Z, Shao Y, Jiang X. Essential roles of the Bcl-2 family of proteins in caspase-2-induced apoptosis. J Biol Chem 2005;280:38271-5.
18. Robertson JD, Gogvadze V, Kropotov A, Vakifahmetoglu H, Zhivotovsky B, Orrenius S. Processed caspase-2 can induce mitochondria-mediated apoptosis independently of its enzymatic activity. EMBO Rep 2004;5:643-8.
19. Guo Y, Srinivasula SM, Druilhe A, Fernandes-Alnemri T, Alnemri ES. Caspase-2 induces apoptosis by releasing proapoptotic proteins from mitochondria. J Biol Chem 2002;277:13430-7.
20. Lassus P, Opitz-Araya X, Lazebnik Y. Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science 2002;297:1352-4.
21. Redon C, Pilch D, Rogakou E, Sedelnikova O, Newrock K, Bonner W. Histone H2A variants H2AX and H2AZ. Curr Opin Genet Dev 2002; 12:162-9.
22. Modesti M, Kanaar R. DNA repair: spot(light)s on chromatin. Curr Biol 2001;11:R229-32.
23. Molinari M. Cell cycle checkpoints and their inactivation in human cancer. Cell Prolif 2000;33:261-74.
24. Bunz F, Dutriaux A, Lengauer C. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 1998;282:1497-501.
25. Charrier-Savournin FB, Château M-T, Gire V, Sedivy J, Piette J, Duli V. p21-mediated nuclear retention of cyclin B1-1 in response to genotoxic stress. Mol Biol Cell 2004;15:3965-76.
26. Rao CV, Desai D, Simi B, Kulkarni N, Amin S, Reddy BS. Inhibitory effect of caffeic acid esters on azoxymethane-induced biochemical changes and aberrant crypt foci formation in rat colon. Cancer Res 1993;53:4182-8.
27. Janakiram NB, Cooma I, Mohammed A, Steele VE, Rao CV. β-Ionone inhibits colonic aberrant crypt foci in rats, suppresses cell growth and induces retinoid X receptor α in human colon cancer cells. Mol Cancer Ther 2008;7:181-90.
28. Jen J, Powell SM, Papadopoulos N. Molecular determinants of dysplasia in colorectal lesions. Cancer Res 1994;54:5523-6.
29. Polyak K, Hamilton SR, Vogelstein B, Kinzler KW. Early alteration of cell-cycle-regulated gene expression in colorectal neoplasia. Am J Pathol 1996;149:381-7.
30. Takayama T, Niitsu Y. In which step does the K-ras mutation occur in colorectal carcinogenesis? J Gastroenterol 2004;39:596-7.
31. Corpet DE, Tache S. Most effective colon cancer chemopreventive agents in rats: a systematic review of aberrant crypt foci and tumor data, ranked by potency. Nutr Cancer 2002;43:1-21.
32. Rao CV, Rivenson A, Simi B. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995;55:1464-72.
33. Yu F-L, Collin P, Bender W, Yamaguchi K, Xue B-H. Studies on he chemopreventive potential of a marine lipid extract, frondanol against breast cancer carcinogenesis at the initiation. Abstract # 3135, Prevention Research 5: Chemoprevention Studies II. Proc Am Assoc Cancer Res 2004;45.
34. Otori K, Sugiyama K, Haseve T, Fukushima S, Esumi H. Emergence of adenomatous aberrant crypt foci (ACF) from hyperplastic ACF with concomitant increase in cell proliferation. Cancer Res 1995;55:4743-6.
35. Shpitz B, Bomstein Y, Mekori Y, et al. Proliferating nuclear antigen as a marker of cell kinetics in aberrant crypt foci hyperplastic polyps, adenomas, and adenocarcinomas of the human colon. Am J Surg 1997;174:425-30.
36. Cohen G, Mustafi R, Chumsangsri A, et al. Epidermal growth factor receptor signaling is up-regulated in human colonic aberrant crypt foci. Cancer Res 2006;66:5656-64.
37. Yang WC, Mathew J, Velcich A, et al. Targeted inactivation of the p21 (WAF1/cip1) gene enhances Apc-initiated tumor formation and the tumor-promoting activity of a Western-style high-risk diet by altering cell maturation in the intestinal mucosal. Cancer Res 2001;61:565-9.
38. Panaretakis T, Laane E, Pokrovskaja K, et al. Doxorubicin requires the sequential activation of caspase-2, PKC{δ}, and JNK to induce apoptosis. Mol Biol Cell 2005;16:3821-31.
39. Paroni G, Henderson C, Schneider C, Brancolini C. Caspase-2-induced apoptosis is dependent on caspase-9, but its processing during UV - or tumor necrosis factor-dependent cell death requires caspase-3. J Biol Chem 2001;276:21907-15.
40. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone-H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-68.
41. 2M arrest following DNA damage in human colon cancer cell lines. Jpn J Cancer Res 1997;88:39-43.
42. Poon RY, Chau MS, Yamashita K, Hunter T. The role of Cdc2 feedback loop control in the DNA damage checkpoint in mammalian cells. Cancer Res 1997;57:5168-78.
43. 2M arrest and apoptosis in bladder cancer cells. Int J Cancer 2005;115:917-23.
44. Seth R, Yang C, Kaushal V, Shah SV, Kaushal GP. p53-dependent caspase-2 activation in mitochondrial release of apoptosis-inducing factor and its role in renal tubular epithelial cell injury. J Biol Chem 2005;280:31230-9.
45. Tinel A, Janssens S, Lippens S, et al. Autoproteolysis of PIDD marks the bifurcation between pro-death caspase-2 and pro-survival NF-κB pathway. EMBO J 2007;26:197-208.
46. Vakifahmetoglu H, Olsson M, Orrenius S, Zhivotovsky B. Functional connection between p53 and caspase-2 is essential for apoptosis induced by DNA damage. Oncogene 2006;25:5683-92.